Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites
Status:
Completed
Trial end date:
2017-12-17
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability
profiles of cenicriviroc (CVC) and its metabolites (M-I and M-II) in participants with
severely impaired hepatic function compared with matched healthy participants following
single-dose administration